Health Wire Burundi
SEE OTHER BRANDS

Your health and wellness news from Burundi

Health Wire Burundi: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Wire Burundi.

Press releases published on September 9, 2025

Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes

Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes

New AI-enabled digital tool empowers patients to confidently manage IBS symptoms and avoid the trigger foods identified by inFoods® IBS testing IBS affects an estimated 40 million adults in the U.S. and hundreds of millions worldwide IRVINE, Calif., Sept. …

CHO Plus Obtains U.S. Patent for Improved Production of Proteins Using Engineered Yeast Cells

CHO Plus Obtains U.S. Patent for Improved Production of Proteins Using Engineered Yeast Cells

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- CHO Plus, Inc. (www.CHO-Plus.com), a leading developer of biopharmaceutical manufacturing technology, announced that U.S. Patent No. 12,404,502 has been issued by the United States Patent and …

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Highlighting Continued Progress with EMA Regarding a Potential Conditional Marketing Authorization Submission for Iopofosine I 131 to Treat Waldenstrom Macroglobulinemia (WM) in the EU; Decision on Track for Late 3Q25/Early 4Q25 Intention to Pursue an …

NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets

NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets

NKGen acquires controlling stake in NKMax, marking a pivotal moment in its transformation into a fully integrated, self-sustaining, cell therapy company with global manufacturing and IP control. Approximately $16.9 million paid to acquire 65% equity stake …

24/7 Market News: Ken Le, Not Stan Lee, to Lead Prodigy Silk’s Super Fiber Deliveries to Global Brands for Kraig Labs

24/7 Market News: Ken Le, Not Stan Lee, to Lead Prodigy Silk’s Super Fiber Deliveries to Global Brands for Kraig Labs

DENVER, Sept. 09, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, analyses Kraig Biocraft Laboratories (OTCQB: KBLB), the undisputed global leader in the …

HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program

HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program

HCW Biologics conducted investigative study to show safe dose levels of its lead drug candidate in non-human primates that were well tolerated at a level significantly higher than the identified efficacious dose level Program has addressed key challenges …

Numab Therapeutics Announces Leadership Transition and Appoints Angehrn Pavik as Chief Executive Officer

Numab Therapeutics Announces Leadership Transition and Appoints Angehrn Pavik as Chief Executive Officer

HORGEN, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, today announced that David Urech, Ph.D., Chief …

Hydrafacial Launches Inaugural Hydrafacial Advisory Councils & Ambassador Network to Fuel Next-Era Innovation and Growth

Hydrafacial Launches Inaugural Hydrafacial Advisory Councils & Ambassador Network to Fuel Next-Era Innovation and Growth

LONG BEACH, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announces the launch of the Hydrafacial Advisory Councils and Ambassador Network – a prestigious collective of …

American Oncology Network and Low Country Cancer Care Welcome Dr. Anton Juncaj

American Oncology Network and Low Country Cancer Care Welcome Dr. Anton Juncaj

Medical oncologist joins Low Country Cancer Care’s physician team SAVANNAH, Ga., Sept. 09, 2025 (GLOBE NEWSWIRE) -- American Oncology Network (AON), one of the nation’s fastest-growing networks of community-based oncology practices, and its partner …

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Confirmed overall response rate (cORR) 68.2% and duration of response (DOR) 14.6 months by BICR in first-line …

Hyperion DeFi Strengthens Leadership Team With Key Appointments to Accelerate DeFi Strategy

Hyperion DeFi Strengthens Leadership Team With Key Appointments to Accelerate DeFi Strategy

Hyunsu Jung Named Interim CEO; CFO Appointment Confirmed, Underscoring Focus on Decentralized Finance Board Expansion and Continued Strategic Advisory Designed to Drive Growth and Execution LAGUNA HILLS, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Hyperion …

Peer Leadership and Resilience Shine in Military Veteran Alpine Challenge

Peer Leadership and Resilience Shine in Military Veteran Alpine Challenge

WHISTLER, British Columbia, Sept. 09, 2025 (GLOBE NEWSWIRE) -- On September 6th, the fourth annual Military Veteran Alpine Challenge (MVAC) was successfully completed in Whistler, British Columbia. Led by the Chronic Pain Centre of Excellence for Canadian …

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on September 4, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) that it has regained …

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Nes-Ziona, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 290470, titled, “ …

Sutter Health Named Among Top 5 Best Workplaces for Innovators by Fast Company

Sutter Health Named Among Top 5 Best Workplaces for Innovators by Fast Company

San Francisco, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Sutter Health has been recognized by Fast Company as one of America’s Best Workplaces for Innovators in 2025. Sutter ranked fourth on the list of just 100 top businesses and organizations that empower their …

Aveanna to Participate at the Jefferies Healthcare Services Conference

Aveanna to Participate at the Jefferies Healthcare Services Conference

ATLANTA, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Jefferies Healthcare Services Conference in Nashville on September 30, 2025. Management will …

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial

New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer’s disease Cognitive outcomes observed in the oral blarcamesine 30 mg Precision Medicine cohort move toward normal aging profiles …

MAPS Board of Directors Names Betty Aldworth and Ismail Lourido Ali as Co-Executive Directors

MAPS Board of Directors Names Betty Aldworth and Ismail Lourido Ali as Co-Executive Directors

Betty Aldworth and Ismail Lourido Ali bring decades of combined experience in drug policy leadership, psychedelic advocacy, and movement building As Co-Executive Directors, Aldworth and Ali reflect MAPS' legacy commitment to serving and strengthening the …

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone extends anticipated cash runway into first quarter of 2027 WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE …

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions